Navigation Links
Alzheimer's Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease
Date:3/21/2011

NEW YORK, March 21, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $170,750 to ADispell Inc. to develop small molecule drugs designed to halt the progression of cognition loss that occurs with Alzheimer's Disease.

(Logo: https://photos.prnewswire.com/prnh/20090805/DC57332LOGO)

ADispell has licensed technology from Cornell University to develop neuroprotective drug candidates targeting a novel site on the nicotinic acetylcholine receptor which is critical for memory processing.  These new drug candidates should improve symptoms, slow the progression of Alzheimer's disease and potentially reverse the course of the disease.  The ADDF's grant will fund a significant pharmacological proof-of-concept program to validate the effects of these compounds in animal models.  

"We are really grateful that the ADDF has found value in our innovations and is supporting our work to move this important technology forward," said Stephen Curry, Ph.D., Chief Executive Officer for ADispell. "We have identified a novel drug target that improves mental performance and compounds that act on that target to improve brain function. These funds will allow us to gain a better understanding of how the compounds affect diseases that cause cognition loss."

"ADispell's unique approach to targeting memory loss holds great promise as a treatment for Alzheimer's disease," said Howard Fillit, M.D., Executive Director for the ADDF.  "The ADDF's investment in ADispell at this critical proof-of-concept stage has the potential to advance their program to the next stage of development."

There are estimated to be more than 5 million patients in the United States and more than 35 million individuals worldwide suffering from Alzheimer's disease.  The disease is believed to have an annual impact of $172 billion on health care in the United States and is projected to increase rapidly in the near future.

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)  

The Alzheimer's Drug Discovery Foundation (ADDF) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 17 countries. 

About ADispell (www.adispell.com)  

ADispell Inc. is a biotechnology development firm with proprietary technology that acts on brain neurons to treat and prevent the cognitive loss caused by Alzheimer's and other diseases. The company was founded in 2009 and has operations in Rochester, NY and Ithaca, NY. Learn more at www.adispell.com.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GE Discovery ST Installed at Imaging Healthcare Specialists
2. Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
3. Dave Anderson and William Thomsen Join SRI Internationals Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
4. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
5. Caliper Life Sciences IVIS® Optical Imaging System Adoption Surpasses 1000 Units: Validated Drug Research, Discovery and Development Tool Enables Advances in Personalized Medicine
6. BioSurplus Selected to Liquidate Discovery Laboratory Equipment
7. PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
8. Reportlinker Adds The Drug Discovery Outsourcing Market
9. Collaborative Drug Discovery Receives New Funding to Support Tuberculosis Drug Discovery Screening Efforts and Industrial-Academic Collaborations
10. TREVENTIS Corporation Founder Wins Prestigious Discovery Award
11. Reportlinker Adds Innovative Drug Discovery in Emerging Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... -- Mitsubishi Tanabe Pharma Corporation (Head Office: ... Masayuki Mitsuka ) has presented data that show ... in 10-14 day cycles for 48 weeks experienced significantly ... Rating Scale-Revised (ALSFRS-R). The data were presented at the ... Dublin, Ireland . In the ...
(Date:12/9/2016)... HARRISBURG, Pa. , Dec. 9, 2016 ... today announced temporary regulations for medical marijuana dispensaries under ... The Pennsylvania Bulletin , and are now available ... what is needed in the plan for operation; process ... the dispensary; as well as where the dispensary facilities ...
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... in millions of US dollars, volume (in units) and ... Femtosecond Lasers and YAG Lasers. The report also ... of these market segements, and global corporate-level profiles of ...
Breaking Medicine Technology:
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... for customers and employees that are both engaging and easy to use. Coming ... Technology, the software company revealed today its plans to roll out new AI-powered ...
(Date:12/8/2016)... ... , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services from ... Messina. , Among the recognitions, the American College of Surgeons' (ACS) named the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... soon after surgery as possible. With this in mind, SIGVARIS has created a ... or blood clot) during bed rest and provide the benefits of graduated compression ...
Breaking Medicine News(10 mins):